Core Viewpoint - The upcoming ban on the production of mercury thermometers in China, effective January 1, 2026, is driving a surge in demand as consumers rush to purchase remaining stock before the prohibition takes effect [1][2]. Group 1: Regulatory Changes - China will fully prohibit the production of mercury thermometers and blood pressure monitors to comply with the Minamata Convention on Mercury, aimed at reducing mercury pollution and its health risks [1]. - The ban is part of a gradual phase-out of mercury-containing products, which has been in place for years, and is intended to promote the transition to mercury-free medical measurement tools [1]. Group 2: Market Response - There has been a notable increase in sales of mercury thermometers, with reports of consumers buying them in bulk due to the impending ban [1][2]. - Alternatives to mercury thermometers are available, including electronic thermometers with comparable accuracy (±0.1-0.2°C) and infrared thermometers that provide rapid readings, suitable for families [2]. Group 3: Public Sentiment and Safety - Many consumers express nostalgia and concern over the discontinuation of mercury thermometers, with some feeling more secure using them [3]. - Medical professionals advise that electronic or mercury-free glass thermometers are sufficient for home use, and there is no need for panic buying [3]. - Existing mercury thermometers can still be used safely, but precautions must be taken if they break, including proper cleanup and disposal [3].

Financial Performance - The basic earnings per share decreased by 79.07% from 0.9207 to 0.1927 yuan [1] - The net profit dropped by 79.23% from 5.49 billion to 1.14 billion yuan [1] - The return on equity fell by 78.48% from 6.97% to 1.50% [1] - Total revenue increased by 3.57% from 173.8 billion to 180 billion yuan [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 15,858.06 million shares, accounting for 39.91% of the circulating shares, a decrease of 1,240.98 million shares from the previous period [1] - Major shareholders include: - Ruan Hongxian with 4,556.13 million shares (11.47%) unchanged [2] - Guangzhou Baiyunshan Pharmaceutical Group with 3,088.03 million shares (7.77%) unchanged [2] - Hong Kong Central Clearing Limited with 2,791.12 million shares (7.03%) decreased by 1,003.11 million shares [2] - New entrants include several funds with varying shareholdings [2] Dividend Distribution - The company announced a dividend distribution of 3 yuan per share (including tax) [4]